- First Online:
- 90 Downloads
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) advocated for use in painful and inflammatory rheumatic and certain nonrheumatic conditions. It may be administered orally or rectally using a convenient once or twice daily regimen. Dosage adjustments are not usually required in the elderly or those with mild renal or hepatic impairment although it is probably prudent to start treatment at a low dosage and titrate upwards in such groups of patients.
Numerous clinical trials have confirmed that the analgesic and anti-inflammatory efficacy of naproxen is equivalent to that of the many newer and established NSAIDs with which it has been compared. The drug is effective in many rheumatic diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and nonarticular rheumatism, in acute traumatic injury, and in the treatment of and prophylaxis against acute pain such as migraine, tension headache, postoperative pain, postpartum pain and pain associated with a variety of gynaecological procedures. Naproxen is also effective in treating the pain and associated symptoms of primary or secondary dysmenorrhoea, and decreases excessive blood loss in patients with menorrhagia. The adverse effect profile of naproxen is well established, particularly compared with that of many newer NSAIDs, and the drug is well tolerated.
Thus, the efficacy and tolerability of naproxen have been clearly established over many years of clinical use, and it can therefore be considered as a first-line treatment for rheumatic diseases and various pain states.
Naproxen possesses the typical pharmacodynamic properties of the nonsteroidal class of anti-inflammatory drugs. In animal studies it exhibits dose-related anti-inflammatory, analgesic and antipyretic effects: on a weight-for-weight basis it is more potent than aspirin and phenylbutazone, and equal to or less potent than indomethacin. Its anti-inflammatory effects are still apparent in adrenalectomised animals, indicating a nonsteroidal mechanism of action. The anti-inflammatory effects of naproxen, and most of its other pharmacological effects, are generally thought to be related to its inhibition of cyclo-oxygenase and consequent decrease in prostaglandin concentrations in various fluids and tissues, including the gastric mucosa, synovial fluid, urine and blood.
In common with other NSAIDs naproxen may induce gastrointestinal microbleeding and endoscopically proven gastrointestinal lesions: it generally produces less effects than aspirin and indomethacin but more than diflunisal, etodolac, nabumetone and sulindac. In clinical practice, however, while the gastrointestinal tolerability of naproxen is better than that of aspirin and indomethacin, there is no definitive evidence to suggest significant differences in tolerability (minor complaints, bleeding or ulceration) between naproxen and other NSAIDs.
Naproxen, like other NSAIDs, is a potent inhibitor of the secondary phase of platelet aggregation. However, at usual therapeutic dosages it has little effect on bleeding time in humans. In general, naproxen does not produce detrimental renal effects in patients with normal renal function although a few changes were reported in some patients with preexisting renal impairment or heart failure. Naproxen does not exert a uricosuric effect.
In normal animals naproxen does not affect collagen metabolism but can inhibit cartilage and bone erosions in animals with adjuvant-induced arthritis. There is no definitive evidence in humans with rheumatic disease that naproxen or any other NSAID can inhibit the progression of cartilage or bone destruction. As occurs with other NSAIDs, naproxen affects leucocyte function reducing chemotaxis, and lysosomal and neutral protease, and collagenase activities in animals.
Naproxen is available in 2 forms: the free acid or the sodium salt. Naproxen and naproxen sodium are pharmacologically and therapeutically equivalent at comparable dosages (naproxen 500mg equals naproxen sodium 550mg). The only difference between the 2 forms is their rate of absorption: naproxen sodium dissolves more rapidly in gastric juice and consequently produces earlier and higher plasma concentrations. Peak plasma concentrations are achieved in about 1 hour with naproxen sodium and 2 hours with naproxen. It is possible that this may provide a faster onset of action with the sodium salt after an initial dose; this would be of relevance in the treatment of acute pain states. Apart from this difference, the post-absorption phase pharmacokinetics of the sodium salt and its parent acid are identical.
Naproxen is completely absorbed after oral and rectal administration. Concomitant administration of food may delay the absorption of orally administered naproxen but does not reduce the extent. Absorption is slower after rectal compared with oral administration, leading to a delay in and lower peak plasma concentrations. Plasma concentrations rise proportionately with dose after oral administration of single doses up to 500mg, but thereafter the increase is less than linear. This is related to increased clearance caused by saturable protein binding. Naproxen is highly protein bound (> 99.5%): the free fraction, however, increases significantly at higher plasma concentrations. The volume of distribution of naproxen is small, being about 10% of bodyweight. The drug readily reaches the synovial fluid and synovial membrane. Naproxen crosses the placental barrier, and minimal transfer occurs to breast milk (about 1% of maternal plasma samples). Approximately 95% of a radiolabelled dose of naproxen is recovered in urine and 3% or less in faeces. 70% of the drug is excreted as unchanged naproxen and the remainder is metabolised to an inactive 6-demethyl metabolite, probably by hepatic microsomal oxidation. The parent compound and metabolite are excreted free or as glucuronide or sulphate conjugates. The elimination half-life is about 12 to 15 hours.
The pharmacokinetic profile of naproxen is generally unaffected to any clinically significant extent by age or the presence of disease. However, free plasma concentrations of naproxen may be increased in elderly patients with rheumatoid arthritis and in patients with hepatic impairment, due to decreased plasma albumin levels. Renal insufficiency has little effect on the pharmacokinetics of naproxen until it is severe. When creatinine clearance is less than 10 ml/min there is a significant decrease in plasma naproxen concentration but an increase in metabolite concentrations. Naproxen is not removed by haemodialysis. Dosage reductions are not therefore required in patients with mild to moderate renal impairment and neither is dose supplementation after haemodialysis.
Naproxen, usually 500 to 1000 mg/day on a once or twice daily basis, administered orally or rectally, has been well studied in controlled clinical trials in patients with rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The drug shows similar analgesic and anti-inflammatory efficacy to usual therapeutic dosages of other commonly used NSAIDs (e.g. aspirin, diclofenac, ibuprofen, indomethacin, ketoprofen, piroxicam), and other less frequently used or newer NSAIDs. As would be expected in such a large number of comparisons, statistically significant differences were found for some assessment parameters but these differences were not of clinical significance and usually related to comparison of therapeutically nonequivalent dosages. With appropriate dosage titration, clinical response to NSAIDs generally appears equivalent (although individual patients may inexplicably respond to or tolerate one NSAID and not others). The therapeutic efficacy of naproxen is maintained during long term treatment up to several years and is associated with a steroid-sparing effect in patients with rheumatoid arthritis.
Several studies have shown that naproxen is effective in the treatment of acute gout and juvenile arthritis but further study is required to allow any definite conclusions concerning its efficacy and tolerability compared with other commonly used agents. Naproxen up to 1000 mg/day has been demonstrated to be an effective analgesic and anti-inflammatory agent for the treatment of acute or chronic nonarticular rheumatic conditions and soft tissue injuries. Its efficacy in these conditions is comparable to that of other commonly used agents. Naproxen is a useful analgesic in a variety of acute pain states, such as migraine, tension headache, postoperative pain, postpartum pain and pain associated with a variety of gynaecological procedures. In the treatment of acute migraine naproxen was comparable to ergotamine. In other acute pain states naproxen was at least as effective as some of the more commonly used ‘pure’ analgesics or their combinations [e.g. paracetamol (acetaminophen), codeine, dextropropoxyphene]. Naproxen has also been used successfully in the prophylaxis of migraine, reducing the severity and frequency of migraine attacks to a similar extent as pizotifen and propranolol.
Naproxen is a well studied agent in the treatment of primary and secondary dysmenorrhoea, alleviating pain and associated symptoms. It reduces symptoms at least as well as other NSAIDs with which it has been compared. In addition, naproxen reduces blood loss and anaemia consequent to menorrhagia.
Naproxen appears to be a particularly effective agent in the control of neoplastic fever and has been used to differentiate between neoplasm-related and infection-related pyrexia in cancer patients with fever of unknown origin. It may also be effective as a general antipyretic agent although further study is required to compare its efficacy relative to that of other standard treatments.
The tolerability profile of naproxen is well established, as extensive experience has been gained with the drug over many years. The drug is generally well tolerated. In common with other NSAIDs the most frequent adverse effects include mild gastrointestinal disturbances and CNS effects, followed by occasional mild skin reactions. Increased age does not appear related to any increase in unwanted effects and there is little evidence to suggest that the nature, severity or frequency of adverse effects is any different with naproxen compared with other NSAIDs. Despite some claims of improved tolerability with some newer NSAIDs, there are no definitive findings to show this. Aspirin and indomethacin may produce a higher frequency of gastrointestinal symptoms and CNS effects compared with naproxen.
As with any drug which has been used so extensively in clinical practice, a number of rare serious adverse effects have been associated with naproxen, which have also been associated with other NSAIDs. They include: gastrointestinal bleeding or ulceration, pseudoporphyria and other severe cutaneous reactions; acute renal failure including papillary necrosis, interstitial nephritis and hyperkalaemia; hepatitis; pulmonary infiltrates with eosinophilia; agranulocytosis; aplastic anaemia; haemolytic anaemia; peripheral neuropathy; aseptic meningitis; and corneal opacity. Patients exhibiting aspirin hypersensitivity may show cross-reactivity with naproxen.
Dosage and Administration
The following dosage schedule refers to naproxen administered as the free acid. If naproxen sodium is used, the dosage is increased by 10% to achieve bioequivalence (naproxen 500mg=naproxen sodium 550mg).
The usual adult maintenance dosage of naproxen in patients with chronic rheumatic disease or chronic pain is 375 to 1000 mg/day after food and on a once or twice daily basis. This may be increased to 1500 mg/day in divided doses for up to 2 weeks to treat acute exacerbations of the disease. For children with juvenile arthritis the recommended dosage is 10 mg/kg in 2 divided doses; a suspension formulation is available to aid administration. In patients with acute conditions such as tendinitis, bursitis, dysmenorrhoea and mild to moderate pain an initial loading dose of 500mg should be administered and followed by 250mg every 6 to 8 hours as required (up to a maximum of 1250 mg/day).
Unable to display preview. Download preview PDF.
- Aabakken L, Bjørnbeth BA, Hofstad B, Olaussen B, Larsen S, et al. Comparison of the gastrointestinal side effects of naproxen formulated as plain tablets, enteric-coated tablets, or enteric-coated granules in capsules. Scandinavian Journal of Gastroenterology 24 (Suppl. 163): 65–73, 1989Google Scholar
- Abate MA, Layne R, Neely J, Alessandri RD. Effect of naproxen and sulindac on the blood-pressure response to atenolol. Abstract. Clinical Research 36: 738A, 1988Google Scholar
- Abramson S, Korchak H, Ludewig R, Edelson H, Haines K, et al. Modes of action of aspirin-like drugs. Proceedings of the National Academy of Sciences 82: 7227–7231, 1985Google Scholar
- Ackerman NR, Kappas K, Maloney P. Possible disease-modifying effects of naproxen in the adjuvant-arthritic rat. Agents and Action 15: 428–434, 1984Google Scholar
- Al-Kurdi M, Hare MJ, Lowles I, Douglas CP. The effect of a prostaglandin-synthetase inhibitor, naproxen sodium, and a placebo on the pain response to carbon dioxide laser treatment of the uterine cervix. Journal of Obstetrics and Gynecology 5: 260–262, 1985Google Scholar
- Amundsen T, Bleken L, Børkje B, Eidsaunet W, Eidsbø P, et al. Variation in response to naproxen and diclofenac in patients with osteoarthritis. Current Therapeutic Research 33: 793–801, 1983Google Scholar
- Anderson LA, Gøtzsche PC. Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in patients with sports injuries. Pharmatherapeutica 3: 531–537, 1984Google Scholar
- Andrade D, Gutiérez-Méndez G, García-Miranda R. Evolución clinica de los esguinces de tobillo tratados con diclofenac potásico y naproxén sódico. Investigación Médica Internacional 11: 130–134, 1984Google Scholar
- Aoki T, Kawaji W, Kuroki Y, Sugaro T, Murota K, et al. Assessment of the clinical usefulness of nabumetone in the treatment of lower back pain, shoulder-arm-neck syndrome and adhesive capsulitis of the shoulder. Shinyaku to Rinsho 37: 2–21, 1988Google Scholar
- Arramon JY, Cayla F, Clement A, Dure B, Franck JL, et al. Action antalgique et tolérance du carbasalate calcique dans les gonarthroses. Etude comparative versus naproxène versus placebo. Semaine des Hôpitaux 63: 1297–1300, 1987Google Scholar
- Australian National Drug Information Service. Profile on naproxen. Australian Journal of Pharmacy 68: 625–639, 1987Google Scholar
- Bassleer C. Effect of naproxen on cartilage matrix. Presented at the 17th ILAR Congress of Rheumatology, Sep 17–23, Rio de Janeiro, 1989Google Scholar
- Baumgartner H, Hohmeister R, Blumenberg-Novaselac N. An observer-blind crossover study to compare the efficacies of flurbiprofen, indomethacin and naproxen given orally and rectally in the relief of night pain and morning stiffness due to rheumatoid arthritis. Journal of International Medical Research 16: 189–196, 1988PubMedGoogle Scholar
- Beermann B, Eriksson LO, Kallner M. A double-blind comparison of naproxen and sulindac in female patients with heart failure. Scandinavian Journal of Rheumatology 15 (Suppl. 62): 32–35, 1986Google Scholar
- Berté F, Feletti F, De Bernardi di Valserra M, Nazzari M, Cenedese A, et al. Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. International Journal of Clinical Pharmacology, Therapy and Toxicology 26: 125–128, 1988Google Scholar
- Blagbrough IS, Daykin MM, Doherty M, Pattrick M, Shaw PN. Synovial fluid and plasma levels of naproxen in osteoarthritis. Journal of Pharmacy and Pharmacology 40 (Suppl C): 153, 1988Google Scholar
- Blaine EH, Haley A, Nelson B. Adverse renal actions of NSAIDs: comparison of sulindac sulfide (SS) and naproxen (N). Abstract no. 3415. Federation Proceedings 42: 875, 1983Google Scholar
- Bravo CA. Carprofeno, nuevo antiinflammatorio no esteroide útil en la enfermedad articular degenerativa. Estudio doble ciegcon 100 pacientes. Investigatión Médica Internacional 13: 131–137, 1986Google Scholar
- Brown CR, Seveluis H, Wild V. A comparison of single doses of naproxen sodium, morphine sulfate, and placebo in patients with postoperative pain. Current Therapeutic Research 35: 511–518, 1984Google Scholar
- Buckingham B, Eriksen E, Uitto J, Larsen M, Kershnar A. Effect of naproxen on collagen cross-linkage in type I diabetes. Abstract no. 754. Diabetes 36 (Suppl. 1): 198A, 1987Google Scholar
- Caille G, du Souich P, Gervais P, Besner JG. Single-dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate. Biopharmaceutics and Drug Disposition 8: 173–183, 1987bGoogle Scholar
- Calvo MV, Dominguez-Gil A. Binding of naproxen to human albumin. Interaction of palmitic acid. International Journal of Pharmaceutics 16: 215–223, 1983Google Scholar
- Calvo MV, Dominguez-Gil A. Interaction of naproxen with cholestyramine. Biopharmaceutics and Drug Disposition 5: 33–42, 1984Google Scholar
- Campana A, Ruspa M. Therapeutic efficacy of naproxen-lysin in dysmenorrhoea. A double-blind study v. naproxen. Clinical Trials Journal 23: 249–256, 1986Google Scholar
- Castillo SS, Absaton MAH, Valencia MFG. Antipiresis aguda con una nuera asociación (naproxén sôdico y acetaminofér) en padecimientos febriles. Investigación Médica Internacional 10: 60–65, 1983Google Scholar
- Chalmers JP, West MJ, Wing LMH, Bune AJC, Graham JR. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clinical and Experimental Hypertension Part A —Theory and Practice A 6: 1077–1093, 1984Google Scholar
- Chang JC. Naproxen test in the differential diagnosis of fever of undetermined origin in patients with cancer. Cancer Therapy and Control 1: 57–66, 1989aGoogle Scholar
- Chin RC, Cheng Y. Comparison of the inhibitory effect of selected nonstcroidal anti-inflammatory drugs (NSAIDs) on bone resorption induced by intcrlcukin IB. Transactions of the 35th Annual Meeting of the Orthopaedic Research Society, p. 119, Feb 6–9, Las Vegas, 1989Google Scholar
- Chlud K, Pangerl S. Comparison of naproxen and piroxicam in the treatment of rheumatoid arthritis: a double-blind, crossover study. Pharmathcrapeutica 4: 113–121, 1985Google Scholar
- Chopra SK, Herdman CP, Laws D, Thomas AM, Wood P. The treatment of osteo-arthritis in general practice. Clinical Trials Journal 26: 401–410, 1989Google Scholar
- Cleland LG. Microbleeding in 28-day naproxen controlled-release (Naprosyn® SR) therapy. Clinical Trials Journal 25: 103–108, 1988Google Scholar
- Cohen A, Ganzalcz MA, Mroszezak EJ, Yec J. Evaluation of the pharmacokinctics of naproxen from a 500mg controllcd-rclease tablet. Current Therapeutic Research 43: 1109–1117, 1988Google Scholar
- CSM Update. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions —2. British Medical Journal 292: 1190–1191, 1986Google Scholar
- D’Agostini G, Liberman J. Estudio clinico multicentrico en America Latina (249 parientes) con una dosisdiaria matutina de 1000mg de naproxen en osteoarthritis. Revista Brasileira de Medicina 42: 77–86, 1985Google Scholar
- Davies AJ. Reduction of menstrual blood loss by naproxen in intrauterine contraceptive device users. International Journal of Gynaecology and Obstetrics 17: 353–354, 1986Google Scholar
- Díaz-Jouanen E. Treatamiento del dolor en osteoartrosis sintomática effecto de diflunisal vs. naproxen. Investigación Médica Internacional 9 (Suppl. 2): 5–8, 1982Google Scholar
- Efron N, Holden BA, Vannas A. Prostaglandin-inhibitor naproxen does not affect contact lens-induced changes in the human corneal endothelium. American Journal of Optometry and Phsyiological Optics 61: 741–744, 1984Google Scholar
- Eidsaunet W, Borkje B, Larsen S, Sandvik L, Spongeen KL. Response to two NSAIDs: diclofenac and naproxen in rheumatoid arthritis. Current Therapeutic Research 33: 966–975, 1983Google Scholar
- Escalante Triay FJ. Comparative clinical study of tiaprofenic acid vs. naproxen in patients with osteoarthritis of the knee. Investigación Médica Internacional 8: 218, 1981Google Scholar
- Farr PM, Diffey BL. Pseudoporphyria due to naproxen. Lancet 1: 1166–1167, 1985Google Scholar
- Fedell R, Strand LJ. Naproxen overdosage. Journal of the American Medical Association 238: 938, 1977Google Scholar
- Fenton SF, Ryan JP, Bensen WG. A double-blind, crossover, multicenter study of piroxicam and naproxen in rheumatoid arthritis. Current Therapeutic Research 44: 1058–1070, 1988Google Scholar
- Fioravanti A, Vaccai D, Dragonetti C, Iudice A, Marcolongo R. Single-blind, randomized, parallel-group study of etodolac and naproxen in patients with osteoarthritis. Current Therapeutic Research 46: 648–653, 1989Google Scholar
- Franchimont P, Bassleer C, Henrotin Y. In vitro effects of naproxen on human chondrocytes. Presented at EULAR, Nov 10–12, Paris, 1988Google Scholar
- Frewin DB. The effect of naproxen therapy on the blood pressure control of hypertensives treated with bevantolol. Abstract no. 112. Clinical and Experimental Pharmacology and Physiology Suppl. 11, 1987Google Scholar
- Gamst ON. Oral naproxen formulations. Scandinavian Journal of Gastroenterology 24 (Suppl. 163): 44–47, 1989Google Scholar
- Gamst ON, Vesje AK, Aarbakke J. Bioavailability of naproxen sodium suppositories. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 99–103, 1984Google Scholar
- Gil JR, Lavin MM. Estudio de la eficacia y tolerancia de tres fármacos antiinflamatorios no esteroides. Investigatión Médica Internacional 10: 342–349, 1983Google Scholar
- Ginsberg F, Famaey JP. A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis. Current Therapeutic Research and Opinion 8: 689–695, 1984Google Scholar
- Grattan CEH, Kennedy CTC. Naproxen induced erythema nodosum. Abstract. British Medical Journal 288: 114, 1984Google Scholar
- Graziani G, Abbiati GA, Dolfini E, Testa R, Velo GP. Pharmacokinetic, pharmacodynamic, and toxicological properties of naproxen gel in laboratory animals. Current Therapeutic Research 42: 480–490, 1987Google Scholar
- Hansten PD, Horn JR. Methotrexate and nonsteroidal anti-inflammatory drugs. Drug Interactions Newsletter 6: 41–44, 1986aGoogle Scholar
- Hansten PD, Horn JR. Nonsteroidal anti-inflammatory drugs: effects on antihypertensive activity of beta-blockers. Drug Interactions Newsletter 6: 1–4, 1986bGoogle Scholar
- Hardy JG, Evans DF, Zaki I, Clark AG, Tönnesen HH, et al. Evaluation of an enteric coated naproxen tablet using gamma scintigraphy and pH monitoring. International Journal of Pharmaceutics 37: 245–250, 1987Google Scholar
- Harry DJ, Hicks H. Naproxen reactions in aspirin-hypersensitive patients. Hospital Formulary 18: 648–649, 1983Google Scholar
- Hodge RH. Double-blind crossover comparison of piroxicam and naproxen in the treatment of active osteoarthritis. Seminars in Arthritis and Rheumatism 3 (Suppl. 1): 3–6, 1985Google Scholar
- Ingemanson C-A, Sikström B. Comparison between diclofenac and naproxen in the treatment of primary dysmenorrhea. Current Therapeutic Research 36: 1203–1209, 1984Google Scholar
- Janke PG, Diggins JB, Currie WJC, Dasgupta PK, Glick EN, et al. A multi-centre study of sulindac versus naproxen in the treatment of elderly osteoarthritis patients. Pharmacotherapeutica 3: 663–667, 1984Google Scholar
- Kajanoja P, Kauste K. Diflunisal compared with naproxen in the treatment of dysmenorrhea. Prostaglandins Leukotrienes and Medicine 15: 153–158, 1984Google Scholar
- Kajanoya P, Vesanto T. Naproxen and indomethacin in the treatment of primary dysmenorrhea. Acta Obstetrica et Gynecologica Scandinavica 87 (Suppl.): 87–89, 1979Google Scholar
- Kaye RL, Smith RD, Gordon RS, Sack B, Menander-Huber KB. Comparative efficacy and tolerability of naproxen 750mg once daily and naproxen 375mg twice daily in the management of rheumatoid arthritis. Proceedings of the 15th International Congress of Rheumatology (ILAR), pp. 26–27, Jun 21–27, 1981, Paris, 1982Google Scholar
- Kucharz EJ, Hawryiuk D. Effect of acetylsalicylic acid and naproxen on collagen solubility and heterogeneity in the rat liver. Pharmozie 42: 117–118, 1987Google Scholar
- Kvarnes L. Naproxen sodium versus pentazocine in treating postoperative pain. Current Therapeutic Research 46: 259–268, 1989Google Scholar
- Landgren BM, Lundström V, Eneroth P, Johannisson E. The effect of a prostaglandin synthetase inhibitor on the hormonal profile and the endometrium in women. American Journal of Obstetrics and Gynaecology 151: 361–368, 1985Google Scholar
- Lanza FL, Rack MF, Royer GL, Seckman CE, Gernaat CM, et al. Gastro-intestinal effects of ibuprofen, naproxen and aspirin in normal volunteers. Clinical Trials Journal 23: 168–177, 1986Google Scholar
- Laothavorn P, Prichanond S. Effect of naproxen on exercise tolerance test in the chronic stable ischemic heart disease patients. Abstract no. PS 231. Journal of the Medical Association of Thailand 67 (Suppl.): 68, 1985Google Scholar
- Lari S, Coli A, Mattioli R, Borghi B, Fabbri G. Acute postsurgical pain in orthopedic surgery: a comparison of sodium naproxen and pentazocine in several analgesic protocols. Current Therapeutic Research 43: 689–697, 1988Google Scholar
- Lee DKH. Effect of etodolac on the prostaglandin concentrations in the kidney of the normal rat. Drug Development Research 9: 305–311, 1986Google Scholar
- Lereim P, Gabor I. Piroxicam and naproxen in acute soft tissue injuries. European Journal of Rheumatology and Inflammation 8: 109–111, 1985Google Scholar
- Lizarazo PH, Cortés MP. Single-blind parallel study comparing naproxen with sulindac and with diclofenac in rheumatoid arthritis. Current Therapeutic Research 34: 701–707, 1983Google Scholar
- Lo TCN, Martin MA. Autoimmune haemolytic anaemia associated with naproxen suppositories. British Medical Journal 292: 1430, 1986Google Scholar
- Lundström V, Landgren BM, Eneroth P, Johannesson E. The effect of a prostaglandin synthetase inhibitor on the hormonal profile and the endometrium in women. Acta Obstetrica et Gynecologica Scandinavica 113 (Suppl.): 77–80, 1983Google Scholar
- Manchester General Practitioner Group. A study of naproxen and ibuprofen in patients with osteoarthritis seen in general practice. Current Medical Research and Opinion 9: 41–46, 1984Google Scholar
- Marsala F, Cavrini P, Bufalino L, Cardini F. Treatment of acute pain of ureteral and biliary colic with naproxen sodium administered by the parenteral route. International Clinical and Pharmacological Research 6: 495–500, 1986Google Scholar
- Martel RR, Klicius J, Metcalf G, Rona GA. Comparative effects of long term treatment with etodolac, naproxen and ibuprofen on articular and bone changes associated with adjuvant arthritis in rats. Agents and Action 15: 403–412, 1984bGoogle Scholar
- Martin PJ, Higginbotham HL. Naproxen simulating 5-hydroxyindoles. Abstract. British Medical Journal 288: 1346, 1984Google Scholar
- Mayon S, Black MM. Pseudoporphyria due to naproxen. British Journal of Dermatology 114: 519–520, 1986Google Scholar
- Mcllwain HH, Platt RD. Piroxicam versus naproxen in the treatment of acute musculoskeletal disorders in athletes. American Journal of Medicine 84 (Suppl. 5A): 56–60, 1988Google Scholar
- McLaughlin G. Choline magnesium trisalicylate vs. naproxen in rheumatoid arthritis. Current Therapeutic Research 32: 579–585, 1982Google Scholar
- McVerry RM, Lethbridge J, Martin N, Mukerjee SK, Littler T, et al. Pharmacokinetics of naproxen in elderly patients. British Journal of Clinical Pharmacology 21: 606P–607P, 1986aGoogle Scholar
- Milsom I, Andersch B, Sundeil G. The effect of flurbiprofen and naproxen sodium on intra-uterine pressure and menstrual pain in patients with primary dysmenorrhea. Acta Obstetrica et Gynecologica Scandinavica 67: 711–716, 1988Google Scholar
- Mroszczak E, Runkel R, Roe R, Ortega E, Segre E. Naproxen pharmacokinetics and metabolism in renal failure. Abstract no. 0544. Presented at the World Conference in Clinical Pharmacology and Therapeutics, London, Aug 3–9, 1988aGoogle Scholar
- Mugnier A, Schneck G, Champion P, Mignon H. Douleurs postopératoires: étude comparative de l’action antalgique du naproxène sodique et du paracétamol. Presse Médicale 13: 429–431, 1984Google Scholar
- Nørrelykke Nissen J, Ehlers N. No additive effect of tranexamic acid and naproxen on corneal deswelling. Acta Ophthalmo-Iogica 64: 291–294, 1986Google Scholar
- Nygren KG, Rybo G. Prostaglandins and menorrhagia. Acta Obstetrica et Gynecologica Scandinavica 113 (Suppl.): 101–103, 1983Google Scholar
- Oddsson E, Gudjónsson H, Thjodleifsson B. Endoscopic findings in the stomach and duodenum after treatment with enteric coated and plain naproxen tablets in healthy subjects. Scandinavian Journal of Gastroenterology 24 (Suppl. 159): 60, 1989Google Scholar
- Ouellette RD, Feinberg A, Laraja R, Rothenberg RE, Welch GW. Naproxen sodium vs acetaminophen plus codeine in post-surgical pain. Current Therapeutic Research 39: 839–845, 1986Google Scholar
- Page SR, Grattan CEH. Pustular reaction to naproxen with cholestatic jaundice. Abstract. British Medical Journal 293: 510, 1986Google Scholar
- Physicians Desk Reference. Naprosyn®. 43 Edition, pp. 2140–2142, Medical Economics Company Inc., New Jersey, 1989Google Scholar
- Plantema F. Worldwide studies comparing piroxicam with naproxen. Acta Obstetrica et Gynecologica 138: 15–17, 1986Google Scholar
- Ragheb M, Powell AL. Lithium interaction with sulindac and naproxen. Journal of Clinical Psychopharmacplogy 6: 150–154, 1986Google Scholar
- Rameis H, Hitzenberger G, Liem KS, Hulkenberg-Tromp D. Comparison of gastrointestinal blood loss induced by cloximate in two formulations and by naproxen. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 96–98, 1984Google Scholar
- Ray PE, Rigolizzo D, Wara DR, Piel CF. Naproxen nephrotoxicity in a 2-year-old child. American Journal of Diseases in Children 142: 524–525, 1988Google Scholar
- Ryan JR, Chremos AN, Vargas R, Johnson CL, McMahon FG. The influence of non steroidal anti-inflammatory drugs (NSAID), [sulindac (S) and naproxen (N)] on natriuretic, diuretic and renin (PRA) response to furosemide (F). Abstract no. C33. Clinical Pharmacology and Therapeutics 35: 271, 1984Google Scholar
- Ryan J, McMahan F, Vargas R, Gotzkowsky S, McNamara D, et al. Effects of salsalate, aspirin and naproxen on plasma renin activity (PRA).and platelet thromboxane (T2 B2 ) synthesis. Abstract no. E66. Arthritis and Rheumatology 29 (Suppl.): S103, 1986Google Scholar
- Sargent J, Solbach P, Alger J, Damasio H, Baumel B, et al. A comparison of naproxen sodium to propranolol hydrochloride or a placebo control for the prophylaxis of migraine headache. Abstract no. 11. Headache 24: 164, 1984Google Scholar
- Scarpa R, Pucino A, Riccio A, Farinaro C, Oriente P. Clinical evaluation of analgesic effect of parenterally administered sodium naproxen (Axer Alfa) in osteoarthritis. Clinical Trials Journal 23: 77–80, 1986Google Scholar
- Scoren RD, Corn H, Rhodes P, Schwarz M, Segal PL, et al. Pain following peridontal surgery: treatment with a nonnarcotic analgesic compared with two iodine combinations. Current Therapeutic Research 42: 463–471, 1987Google Scholar
- Shah J, Mroszczak E, Bynum L, Fratis A, Kiang C. Bioequivalence comparison of enteric-coated (EC) naproxen versus standard naproxen tablets. Abstract 1613. Pharmaceutical Research 6 (Suppl): S232, 1989Google Scholar
- Solheim LF, Rönningen H, Langeland N. Effects of acetylsalicylic acid and naproxen on the synthesis and mineralization of collagen in the rat femur. Archives of Orthopaedic and Traumatic Surgery 105: 1–4, 1986bGoogle Scholar
- Solheim LF, Rönningen H, Langeland N. Effects of acetylsalicylic acid and naproxen on the mechanical properties of intact femora in rats. Archives of Orthopaedic and Traumatic Surgery 105: 5–10, 1986cGoogle Scholar
- Solheim LF, Rönningen H, Langeland N. Effects of acetylsalicylic acid and naproxen on bone resorption and formation in rats. Archives of Orthopaedic and Traumatic Surgery 105: 137–141, 1986dGoogle Scholar
- Svendsen VG. Effects of sulindac and naproxen on patients with glomerulonephritis and moderately impaired renal function. Abstract. Scandinavian Journal of Rheumatology 59 (Suppl.): 94, 1986Google Scholar
- Svendsen VG, Gerstoft J, Hansen TM, Christensen P, Lorenzen I. The renal excretion of prostaglandins and changes in plasma renin during treatment with either sulindac or naproxen in patients with rheumatoid arthritis and thiazide treated heart failure. Journal of Rheumatology 11: 779–782, 1984PubMedGoogle Scholar
- Szórády I, Martonyi E, Santa A. Antipyretic effect of naproxen in children. Therapie 43: 155, 1988Google Scholar
- Taborn JD, Burch FX, Caldwell JR, Kantrowitz FG, Louie JS, et al. Comparative study of once a day dosing with naproxen versus twice a day dosing of sulindac in patients with rheumatoid arthritis. Proceedings of the 15th International Congress of Rheumatology (ILAR), Jun 21–27, 1981, Paris, pp. 23–25, 1982Google Scholar
- Tannenbaum H, Esdaile J, Topp JR, Prat A, Rostogi RB, et al. A double-blind, multicenter, controlled study on diclofenac (Voltaren®) and naproxen in patients with rheumatoid arthritis. Current Therapeutic Research 35: 357–362, 1984Google Scholar
- Tütinen S, Nissilä M, Ruutsalo HM, Isomäki H. Effect of non-steroidal anti-inflammatory drugs on the renal excretion of uric acid. Clinical Rheumatology 2: 233–236, 1983Google Scholar
- Treves TA, Korizyn AD, Streifler M. Naproxen in the treatment of acute migraine attacks. Abstract. Neurology 36 (Suppl. 1): 101, 1986Google Scholar
- Trondstad R, Bell H, Holler T. Endoscopic evaluation of the effect of naproxen tablets and suppositories on the gastric mucosa in healthy volunteers. Scandinavian Journal of Gastroenterology 23 (Suppl. 145): 70, 1988Google Scholar
- Turi G, Boscaro C, De Bastiani G. Double-blind comparative study of isoxicam and naproxen in the treatment of patients with osteoarthritis. Current Therapeutic Research 33: 83–88, 1983Google Scholar
- van den Ouweland FA, Jansen PAF, Tan Y, van de Putte LBA, van Ginneken CAM, Gribnau FWJ. Pharmacokinetics of high-dosage naproxen in elderly patients. International Journal of Clinical Pharmacology, Therapy and Toxicology 26: 143–147, 1988bGoogle Scholar
- van der Spek P, Warson F, van Overberg L, Peters O. Postoperative jaundice associated with naproxen. Abstract no. 84. Naunyn-Schmiedeberg’s Archives of Pharmacology 330 (Suppl.): R20, 1985Google Scholar
- Wallis PJW, Lodwick R, Sirha SK, Constable TJ. Effect of naproxen on renal haemodynamics in elderly patients. Abstract no. 15. British Journal of Rheumatology 26 (Suppl.): 9, 1987Google Scholar
- Warrington SJ, Horton M, Davies IB. High dose tiaprofenic acid, naproxen and aspirin: comparison of effects on gastrointestinal blood loss. British Journal of Clinical Pharmacology 18: 301P–302P, 1984Google Scholar
- Watson WA, Freer JP. Effects of naproxen and sulindac in arthritic patients with renal impairment Abstract 26E. Pharmacotherapy 9: 177, 1989Google Scholar
- Wilhelmson L, Jaderling J. A double-blind crossover study of piroxicam and naproxen sodium in the treatment of primary dysmenorrhea. Abstract. European Journal of Rheumatology and Inflammation 8: 121–122, 1985Google Scholar
- Williams PL, Ansell BM, Bell A, Cain ARR, Chamberlain A, et al. Multicentre study of piroxicam versus naproxen in juvenile chronic arthritis, with special reference to problem areas in clinical trials of nonsteroidal anti-inflammatory drugs in childhood. British Journal of Rheumatology 25: 67–71, 1986PubMedGoogle Scholar
- Willkens R, Crain D, Nussdorf RT, Partridge R, Sokoloff M, et al. Naproxen and sulindac in the treatment of osteoarthritis -a crossover comparison. Current Therapeutic Research 34: 45–58, 1983Google Scholar
- Wilson Downie W. Comparative studies of isoxicam in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 12 (Suppl. 2): 170–174, 1982Google Scholar
- Wiseman RL, Sodergren J, Guttadauria M, Ryan AJ. Treatment of acute musculoskeletal disorders with piroxicam: results of a double-blind multicenter comparison with naproxen. Current Therapeutic Research 42: 974–987, 1987Google Scholar
- Zecchi V, Rodriguez L, Tartarini A, Chiarini A, Valenti P. In vitro studies of naproxen and its sodium and piperazine salts. Pharmaceutica Acta Helvetiae 59: 91–94, 1984Google Scholar